Evaluating Immune Cell Receptors in Lupus Patients
Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus
This study is testing how certain immune cell receptors behave in people with lupus to see if they are linked to active or inactive stages of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Tours Academic / other |
| Locations | 1 site (Tours) |
| Trial ID | NCT05859191 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells and monocytes in patients with systemic lupus erythematosus. It aims to compare the receptor expression in active or newly diagnosed lupus patients against those with inactive disease. By understanding the role of FcRn and other Fc gamma receptors in the immune response, the study seeks to clarify their involvement in the pathophysiology of lupus. Blood samples will be collected for analysis to assess the relationship between receptor expression and disease activity.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of systemic lupus erythematosus, whether newly diagnosed or in relapse.
Not a fit: Patients with autoimmune diseases other than lupus or those under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of lupus pathophysiology and lead to improved therapeutic strategies.
How similar studies have performed: While the role of FcRn in autoimmune diseases has been explored, this specific investigation into its expression in lupus patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's * Lupus patient, newly diagnosed or known, untreated or in relapse * Lupus patient considered stable by the treating practitioner * Requiring blood sampling for follow-up Exclusion Criteria: * Main autoimmune disease other than lupus * Patient under legal protection, guardianship or curators * Opposition to data processing
Where this trial is running
Tours
- University Hospital — Tours, France (Recruiting)
Study contacts
- Principal investigator: Yanis RAMDANI — CHRU de Tours
- Study coordinator: Yanis RAMDANI
- Email: yanis.ramdani@univ-tours.fr
- Phone: 0234378919
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.